237 related articles for article (PubMed ID: 21653999)
1. p21-activated kinase 1: PAK'ed with potential.
Ong CC; Jubb AM; Zhou W; Haverty PM; Harris AL; Belvin M; Friedman LS; Koeppen H; Hoeflich KP
Oncotarget; 2011 Jun; 2(6):491-6. PubMed ID: 21653999
[TBL] [Abstract][Full Text] [Related]
2. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
Ong CC; Jubb AM; Haverty PM; Zhou W; Tran V; Truong T; Turley H; O'Brien T; Vucic D; Harris AL; Belvin M; Friedman LS; Blackwood EM; Koeppen H; Hoeflich KP
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7177-82. PubMed ID: 21482786
[TBL] [Abstract][Full Text] [Related]
3. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP
Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
[TBL] [Abstract][Full Text] [Related]
6. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
7. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
8. PAKs in human disease.
Chan PM; Manser E
Prog Mol Biol Transl Sci; 2012; 106():171-87. PubMed ID: 22340718
[TBL] [Abstract][Full Text] [Related]
9. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
10. Role of p-21-activated kinases in cancer progression.
King H; Nicholas NS; Wells CM
Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
[TBL] [Abstract][Full Text] [Related]
11. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.
Huynh N; Liu KH; Baldwin GS; He H
Biochim Biophys Acta; 2010 Sep; 1803(9):1106-13. PubMed ID: 20595063
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
13. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
Yi C; Wilker EW; Yaffe MB; Stemmer-Rachamimov A; Kissil JL
Cancer Res; 2008 Oct; 68(19):7932-7. PubMed ID: 18829550
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.
Eswaran J; Li DQ; Shah A; Kumar R
Clin Cancer Res; 2012 Jul; 18(14):3743-9. PubMed ID: 22595609
[TBL] [Abstract][Full Text] [Related]
15. Role of p21-activated kinases in cardiovascular development and function.
Kelly ML; Astsaturov A; Chernoff J
Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
[TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.
Yi C; Maksimoska J; Marmorstein R; Kissil JL
Biochem Pharmacol; 2010 Sep; 80(5):683-9. PubMed ID: 20302846
[TBL] [Abstract][Full Text] [Related]
17. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest.
Woo TG; Yoon MH; Hong SD; Choi J; Ha NC; Sun H; Park BJ
Oncotarget; 2017 Apr; 8(14):23690-23701. PubMed ID: 28423593
[TBL] [Abstract][Full Text] [Related]
19. PAK signalling during the development and progression of cancer.
Radu M; Semenova G; Kosoff R; Chernoff J
Nat Rev Cancer; 2014 Jan; 14(1):13-25. PubMed ID: 24505617
[TBL] [Abstract][Full Text] [Related]
20. PAK1 as a therapeutic target.
Kichina JV; Goc A; Al-Husein B; Somanath PR; Kandel ES
Expert Opin Ther Targets; 2010 Jul; 14(7):703-25. PubMed ID: 20507214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
